Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Recommends Lucentis In 20 Percent Of Wet AMD Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Draft guidance by U.K. watchdog recommends Lucentis in certain patients with wet AMD but does not recommend Macugen.

You may also be interested in...



UK’s NICE Proposes Lucentis Dose-Capping Approach To Coverage For Wet AMD

Agency releases new draft in response to criticism of an earlier recommendation that would limit payment to treatment in the second affected eye.

UK’s NICE Proposes Lucentis Dose-Capping Approach To Coverage For Wet AMD

Agency releases new draft in response to criticism of an earlier recommendation that would limit payment to treatment in the second affected eye.

Lucentis SAILOR Trial Hits Choppy Water

Interim analysis of neovascular AMD patients shows a higher incidence of stroke in patients treated with 0.5 mg dose of Lucentis.

Related Content

Topics

UsernamePublicRestriction

Register

PS066182

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel